Introduction
Helicobacter pylori has been linked with an increasing number of conditions since its first suggested association with gastritis, now well established. Knowledge about the pathogenesis of peptic ulcer disease (PUD) has been revolutionised by the isolation of H pylori, and, as a natural consequence of this, the management of PUD has completely changed from one of primarily acid suppression to one of primarily bacterial eradication. The causal association between colonisation by H pylori, PUD, and gastric cancer places H pylori as an important human pathogen. The link between colonisation by H pylori and the risk of developing various forms of gastric neoplasm raises the exciting prospect of reducing the risk of neoplasm development by some form of eradication therapy at a population or even individual level. A natural corollary of this is the requirement of an eVective screening procedure to determine colonisation status. In addition, the possible association between the widespread pathophysiological eVects of chronic inflammation in the stomach and the risk of ischaemic heart disease, growth retardation, and gall stones also suggests the need for cost-eVective management protocols.
Generally, there are a number of factors that must be included in an eVective protocol for all aspects of disease management. For example, there should be an accurate diagnostic procedure at an individual level and a cost-eVective population screening procedure. Also, the ability to determine prognostic indicators may influence management of the disease and there should be an eVective follow up protocol to establish eYcacy of treatment and recurrence of disease. More specifically, with respect to determining colonisation by H pylori and associated disease, blood tests are one of the two non-invasive techniques available; the other is the urea breath test (UBT).
Antibody tests for H pylori

EVALUATION OF ANTIGEN
Several diVerent antigen preparations have been tested. Initially, crude sonicates were used, and, although the sensitivity of the test was high, the specificity was relatively low compared with other diagnostic tests such as culture or histology, because of false positives caused by non-specific cross reactions with other organisms-for example, Campylobacter sp.
Comparison of a whole cell preparation and an acid-glycine extract 1 showed enrichment of some immunodiagnostic antigens in the acidglycine extract (the 54 and 69 kDa proteins) but complete loss of others (the 29 and 120 kDa proteins). Further, although the intention was to reduce non-specific cross reactions, they were still detectable when assessed by western blotting. A more extensive study 2 compared crude sonicates with ultracentrifuged whole cell sonicates and acid-glycine extracts and antigen fractions separated by sodium dodecyl sulphatepolyacrylamide gel electrophoresis. The greatest discrimination between H pylori positive and negative sera was found with high molecular mass fraction antigens, but whole cell sonicates were better than acid-glycine extracted antigens. A further comparison of four diVerent antigen preparations (crude sonicate, acid-glycine extract, acid-glycine extract of a flagellate organism, and urease enriched fraction) showed the crude sonicate to have the highest sensitivity but the lowest specificity. 3 A study using more purified antigen prepared by fast protein liquid chromatography (FPLC) or monoclonal antibody capture generally showed lower sensitivities of the purified antigens compared with an acid-glycine extract, with specificities of 100% for most of the fractions. 4 In one serological assay using the 120 kDa (CagA) protein purified by size exclusion chromatography 5 and compared with a whole cell preparation, the sensitivities and specificities were 96 and 100% and 92 and 60% respectively for the whole cell preparation. Several other studies have also compared diVerent antigen preparation as the basis for serological tests. [6] [7] [8] [9] [10] [11] These results show, not unexpectedly, that there is a trade oV with antigen purification between loss of sensitivity and increased specificity. Immunoblots have shown qualitative and quantitative diVerences in the pattern of response in patients, and this emphasises that the type of strain of H pylori and the method of preparation of the antigens for serological tests may be critical to the test parameters. It is possible that a judicious combination of purified antigens may maximise both sensitivity and specificity, and many second generation serological tests use purified or combinations of purified antigens. Table 1 shows the sensitivity and specificity of some antigen preparations and combinations.
EVALUTATION OF COMMERCIALLY AVAILABLE SEROLOGICAL ASSAYS
ELISA kits
Many publications have compared either single or many kits one against another [12] [13] [14] [15] [16] [17] [18] in a defined population, usually patients with dyspepsia or PUD or symptomatic individuals. Table 2 lists the main commercial serological assays available for the detection of H pylori. A comparison of the use of three kits for 76 patients using known culture positive cases showed comparable sensitivity and specificity of between 88 and 96% and 86 and 96% respectively. The inter-and intra-laboratory assay variation was low. The three kits used antigens of diVerent purity: Pyloristat (urease enriched fractions), HelicoG (acid-glycine extract), Premier HP (high molecular mass cell associated proteins). 19 In a further test on 95 dyspeptic patients, the Cobas Core anti-H pylori immunoglobulin EIA-G, which uses an FPLC purified antigen, had a sensitivity and specificity of 94 and 98% respectively and was superior to the rapid urease test (RUT) (88 and 96%) and culture (70 and 98%) when compared with histology. 20 A laboratory comparison of the three kits was carried out, which included modified Pyloriset EIA-G update kit and Malakit EIA-G 21 , on serum samples from 154 dyspeptic patients. Serological results were compared with those using culture/histology/ RUT as the "gold standard". The updated Pyloriset showed an improved sensitivity but reduced specificity compared with previous results for this kit from other studies on equivalent groups of patients. A single laboratory comparison of eight kits was undertaken 22 on 84 dyspeptic patients and compared with histology and UBT. The results showed that all the kits had comparable sensitivity (90-100%) but more variable and lower specificity (76-96%) . Indeterminate (grey zone) results occurred with some kits in up to 12% of the readings, although Premier HP, Pyloriset EIA-G, and HelicoG were calibrated so as not to give grey zone results (the latest version of the last of these kits, HelicoG2, however, does not have a grey zone range). The kit giving the highest percentage of grey zone results was GAP IgG. In this study Pylori ELISA II and Premier HP were particulary eVective.
A multilaboratory comparison of eight kits 23 also showed that all the kits tested were broadly comparable. Some laboratories experienced diYculties with some kits and some kits showed high inter-laboratory variation.
Overall the Pyloriset EIA-G and Roche MTP kits seemed to be the best. Again most of the kits produced some indeterminate results but this varied between kits (Roche, 0.9%; Hel-p Test, 13%). Table 3 gives the published sensitivity, specificity, positive, and negative values of these kits. 
Latex agglutination kits
The agglutination format is not as frequently used as the ELISA format and there have been fewer published evaluations. [24] [25] [26] [27] [28] [29] [30] Pyloriset Dry has replaced Pyloriset LA; it diVers in the test procedure, but both use latex beads coated with an acid-glycine extract of H pylori. Both tests detect IgM, IgA, and IgG. The latex agglutination test is more convenient than the ELISA format for near patient testing and has comparable sensitivity and specificity with the ELISA tests (table 4) .
Near patient testing
There is a perceived unmet clinical need for near patient testing of patients for H pylori infection, and several companies have developed rapid tests. Most of the tests consist of one step using whole blood, but others require serum separation, which diminishes their usefulness as near patient kits. With one test kit, variation in sensibility and specificity were noted depending on whether capillary or venous blood was used. Comparatively few assessments have been published. 31 32 The Helisal rapid blood test (Helisal RBT, now superseded by Helisal One Step) had a sensitivity and specificity of 88 and 91% and a positive predictive value and negative predictive value of 92 and 86% when compared with histology, culture, RUT, and UBT in 154 dyspeptic patients. 33 These results compared with 93 and 87% sensitivity and specificity respectively for an ELISA test (HelicoG) in 109 of the patients. Another assessment on 203 patients 34 compared with RUT/histology gave a sensitivity and specificity of 82 and 91%, and in this study there was concurrence of results whether venous or capillary blood was used. When Helisal was compared with a laboratory ELISA, its sensitivity and specificity were 83 and 78% respectively. 35 Other studies have found much lower specificity (55%) when compared with RUT/histology/culture 36 37 (table 4). Inter-and intra-laboratory comparisons have not yet been performed and published for these kits, but a recent publication does not support the use of these kits as presently formulated for near patient testing. 38 
EFFECT OF POPULATION ON SEROLOGICAL
RESULTS
Most assessments have been made in adults who were dyspeptic or asymptomatic. It is recognised from sero-epidemiological studies that diVerent ethnic populations have widely diVering prevalences of infection and that the assay cut-oV value may have to vary to reflect this. Similarly the positive and negative predictive values of the various serological tests may vary according to age, drug administration, or coexistent disease in the population or individual under investigation. Studies in a group of children and in the elderly have shown decreased specificity of the serological tests when compared with culture and histology. 39 In the elderly this can often be due to atrophic gastritis and reduction in colonisation by H pylori. Apart from this age related eVect on the accuracy of serological tests, the use of non-steroid anti-inflammatory drugs 40 can also aVect the test accuracy, as can coexistent disease such as HIV infection, 41 cystic fibrosis, 42 and cirrhosis. 43 
SEROLOGY IN DIAGNOSIS AND SCREENING
Serology can only give evidence of contact with H pylori and does not necessarily indicate a current infection. This is more accurately diagnosed using a UBT. Serology, however, like the UBT, is a global test and is not aVected by sampling errors, as are the biopsy based tests. In a study comparing all the diagnostic methods available, serology had a sensitivity and specificity of 98 and 95% respectively compared with 98 and 100% (culture), 96 and 100% (PCR), 98 and 98% (histology), 90 and 100% (RUT), and 100 and 100% ( 13 C-UBT), 44 although lower values for the sensitivity and specificity have been obtained in other studies. For example, comparing serology with RUT, sensitivities of 74 and 90% and specificities of 89 and 96% respectively were obtained in one study 45 and sensitivities and specificities of 96 and 88% for serology were obtained in another study when compared with UBT (96 and 100%), RUT (92 and 92%), and histology (96 and 91%). 46 The relative sensitivity and specificity of serology obtained in another study, when compared with other diagnostic methods, depended on the population studied, the number of individuals investigated, and the type of serological assay There are several possible management algorithms: to treat empirically; to use a screening test and either treat or proceed to endoscopy on the basis of the results; to examine every symptomatic patient by endoscopy. As the latter is an expensive option, various screening strategies have evolved to decrease the number of endoscopies performed. Other factors that need to be taken into account in a management algorithm are age (if over 45 years the patient should proceed to endoscopy without necessarily having a serological test), use of non-steroid anti-inflammatory drugs, and worrying symptoms. Several studies have shown that screening dyspeptic patients using serological tests can be cost-eVective in reducing the endoscopy workload by up to 30% without missing significant pathology. 47 48 Patients who are positive on serological testing can then go on to endoscopy to verify the presence of PUD and hence be started on treatment, or may proceed directly to treatment. However, other studies have shown that if a screening strategy is adopted, significant pathology in some populations can be missed, 49 and we do not recommend it as a routine practice.
An alternative screening strategy is the use of a symptom questionnaire, and these have been reported to save a similar percentage of endoscopies as serological screening. In one direct comparison of symptom questionnaires with serological screening in 315 patients, 50 the latter detected more PUD than the questionnaires, but one of the questionnaires was more cost-eVective in avoiding unneeded endoscopies. In addition, a cost analysis 51 of adopting a screening protocol using serological tests compared with empirical treatment with H 2 receptor antagonists or an eradication protocol showed that, although the eradication regimen was cheaper than suppressive treatment with H 2 receptor antagonists, this was oVset by the cost of screening to such an extent that savings were only achieved after eight years. In children, the most cost-eVective approach was empirical antisecretory treatment; however, the cost benefit of screening or empirical treatment when compared with direct endoscopy was diminished if the relative costs of endoscopy were low or the recurrence rate of symptoms was high (>65%). 52 Another cost-benefit analysis 53 showed that the eYcacy of serological testing as a screening procedure depended on a response rate of more than 10% in non-ulcer dyspepsia (NUD) to eradication of H pylori, a saving of more than $4000 for ulcer prevention and a prevalence rate of more than l0% of PUD in all dyspeptic patients. Other studies have shown that serological testing can be useful in screening long term dyspeptic patients on suppressive H 2 receptor antagonists in a general practice setting. In one practice of 7100 patients, 17 were confirmed as H pylori positive by serology and given an eradication protocol. Four months after successful eradication (confirmed by a UBT), 76% of the patients were symptom free. 54 Obviously these percentages may fall with prolonged follow up of the patient.
In addition to screening as a means of reducing the cost of managing dyspepsia, there may be a place for population screening for H pylori infection as a means of preventing gastric cancer. Epidemiological evidence suggests that 31-87% of gastric cancers may be attributable to colonisation by H pylori, 55 and it is feasible that eradicating H pylori from an asymptomatic population may reduce the occurrence of gastric cancer. Such interventional studies are underway, but it will be years before any accurate conclusions can be drawn. It is preferable to substantiate the reversibility of premalignant conditions such as atrophic gastritis and intestinal metaplasia after successful eradication of H pylori before wholesale screening is adopted. However, a cost-benefit analysis 56 showed that, if 30% of gastric cancers were preventable by a screening eradication protocol, the costeVectiveness was $25 000 per year of life saved, and this value was approximately maintained even if the success was only 5% if undertaken in high risk groups.
SEROLOGICAL TESTS FOR THE ASSESSMENT OF ERADICATION OF H PYLORI
After successful eradication of H pylori, antibody levels fall slowly over several months. In one study of 144 patients given eradication treatment, the IgG titre had fallen by 30% by six weeks after eradication and continued to fall over the succeeding nine months. 57 Similar reductions in IgG have been found in other studies, 58 and, although this can be used to assess successful eradication, it is not as convenient as the UBT.
The length of time required to carry out the serological tests mitigates against their use for assessing the success of therapy, as most patients and doctors would prefer to have a more speedy answer, if available. However, the merits of a relatively delayed serological result compared with a more speedy result from the UBT have not been assessed.
SEROLOGICAL MARKERS OF PATHOGENICITY
The high prevalence of H pylori infection throughout the world compared with the relatively low prevalence of the gastroduodenal diseases linked with the infection raises the question of whether all H pylori have the same clinical impact. It has been shown that some genes (vacA, cagA, iceA) confer diVerent biological properties, such as proinflammatory, cytotoxic, and vacuolating activity, which could enhance the in vivo pathogenicity of the bacteria. 59 CagA and VacA are the most studied of their gene products and are reported to be linked with the more serious diseases. Knowledge of the CagA and VacA status of H pylori infection could be relevant for treatment and for prevention of the possible complications of infection. It is therefore important to diagnose the type of infecting organism. This is serologically possible since CagA protein is highly immunogenic: in fact, more than 95% of subjects infected by cagA positive H pylori strains develop a serologically detectable response to the gene product (anti-CagA), compared with 0% of uninfected patients. 60 However, both the structure of the VacA proteins and the serological response to it are only just being clarified and data are still scanty. These and other as yet undiscovered proteins could therefore lead to the identification of "bad", "very bad", "neutral", or even "good" H pylori strains, as recently speculated by Blaser. 61 The serological techniques currently available to determine the cytotoxic type of infecting strains are western blotting and ELISA. A novel recombinant immunoblott assay (RIBA-SIA; Chiron Corp., Emeryville, California, USA) has recently been proposed which contains individual bands for whole H pylori lysate, recombinant CagA, and VacA. In a recent evaluation of anti-CagA and anti-VacA reactivity by RIBA-SIA in large populations of both asymptomatic subjects and patients with diVerent pathologies, anti-CagA mainly but also anti-VacA reactivities were found to be more prevalent in patients with severe gastroduodenal pathology (table 5) . 62 Similarly the seroprevalence of anti-CagA reactivity assessed by ELISA (Helori-CTX; Eurospital, Trieste, Italy) was confirmed as being higher in H pylori positive subjects with gastric or duodenal ulcer than asymptomatic subjects or patients with NUD. 63 The results of a large multicentre study carried out in Italy involving over 3000 patients examined by endoscopy in more than 90 endoscopy units have recently been published. 64 CagA prevalence was assessed by ELISA in this large population, and the preliminary results in over 1300 patients confirm the association between CagA and major gastroduodenal pathology (table 6) .
Many similar, although smaller, studies have previously shown the association between CagA as a marker for PUD and gastric cancer, 65 66 although other studies have not found this association. 67 
MARKERS OF GASTRIC INFLAMMATION AND H PYLORI
To distinguish PUD (in which the eradication of H pylori is recommended) from NUD (in which the role of H pylori is controversial), it is necessary to perform an endoscopy. Neither serological tests nor UBT give any quantitative information that would help to diVerentiate between these two conditions. 68 However, measurement of blood markers of gastric inflammation may give some clinical information that is useful in the management of H pylori related disease.
Gastrin H pylori infection is associated with a set of well recognised disturbances to normal gastric physiology. Plasma gastrin levels are elevated in H pylori infection (150 ng/ml) compared with control levels (50 ng/ml) as a consequence of inhibition of somatostatin production. After eradication of H pylori the plasma gastrin levels return to normal.
Higher levels of plasma gastrin are found in corpus gastritis than in antral gastritis, 69 but there is no significant diVerence between the levels in gastritis compared with ulceration. 70 
Pepsinogen
Variations in concentrations of pepsinogen (PG) I and II and the PGI:II ratio can occur with age, weight, smoking, and chronic renal failure. Increases in both PGI (73 ng/ml compared with 50 ng/ml) and PGII (24 ng/ml compared with 10 ng/ml) with a reduction in the PGI:II ratio (3.6 compared to 6.2) are found in H pylori associated gastritis compared with H pylori negative individuals. 71 Some studies have shown that PGI levels are even further elevated in H pylori associated PUD compared with those without PUD, 72 and the elevation correlates with the degree of inflammation. A high PGI:II ratio is found in ulceration associated with the Zollinger-Ellison syndrome. In H pylori associated gastritis the increase in PGI is least in corpus only gastritis and highest in predominantly antral gastritis. Reduction in both PGI and PGII and normalisation of the ratio can be used to confirm successful eradication of H pylori, 73 74 although a decrease in PGII is the most accurate biomarker of eradication compared with PGI, serology, and serum gastrin. 75 Variation in the levels and ratio of PG can be used to predict the presence of more serious gastric pathology. Used as a screening test in an asymptomatic population, a low PGI combined with H pylori positivity can predict gastric atrophy with a sensitivity and specificity of 88 and 92% respectively. 76 A high serum IgA anti-H pylori antibody level associated with a 
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group.bmj.com on October 21, 2017 -Published by http://gut.bmj.com/ Downloaded from decreased PGI (<50 ng/ml) correlates with an increased risk of gastric cancer, with an odds ratio of 5.95 in one study population. 77 Conversely there is an inverse correlation between serum IgG anti-H pylori antibody levels and the extent of gastric metaplasia, but only in those individuals that have normal PGI levels. 78 Screening strategies have been developed to detect gastric adenocarcinoma using a combination of H pylori positivity and PG and gastrin levels. 79 80 A study of 686 patients, of which 150 had gastric adenocarcinoma, showed that age above 62 years, low PGI levels, low PGI × gastrin value, and low PGI:gastrin ratio were indicative of gastric adenocarcinoma, with the value of serum PGI being the most important.
Conclusions
The exact role of serological testing in the management of H pylori infection is yet to be defined. However, used as a screening procedure, it can reduce endoscopy workload and cost, although the savings may take several years to accumulate.
Used in conjuction with blood levels of gastrin and PGs, these tests can suggest the presence of H pylori associated gastritis and be used to screen for serious gastroduodenal pathology, although further work is required to clarify their usefulness in this aspect.
The role of H pylori in NUD will aVect how these blood tests are used in the management of Helicobacter infections. Currently, eradication of H pylori is only recommended in cases of PUD, and endoscopy is required to diVerentiate PUD from NUD. Therefore blood tests that could achieve this diVerentiation may reduce the endoscopy workload even further.
